In silico prediction of drug-induced myelotoxicity by using Naïve Bayes method

Drug-induced myelotoxicity usually leads to decrease the production of platelets, red cells, and white cells. Thus, early identification and characterization of myelotoxicity hazard in drug development is very necessary. The purpose of this investigation was to develop a prediction model of drug-induced myelotoxicity by using a Naïve Bayes classifier. For comparison, other prediction models based on support vector machine and single-hidden-layer feed-forward neural network  methods were also established. Among all the prediction models, the Naïve Bayes classification model showed the best prediction performance, which offered an average overall prediction accuracy of $$94 \pm 0.9~\%$$94±0.9% for the training set and $$82 \pm 2.5~\%$$82±2.5% for the external test set. The significant contributions of this study are that we first developed a Naïve Bayes classification model of drug-induced myelotoxicity adverse effect using a larger scale dataset, which could be employed for the prediction of drug-induced myelotoxicity. In addition, several important molecular descriptors and substructures of myelotoxic compounds have been identified, which should be taken into consideration in the design of new candidate compounds to produce safer and more effective drugs, ultimately reducing the attrition rate in later stages of drug development.

[1]  D Parent-Massin,et al.  Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  D. Rogers,et al.  Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up , 2005, Journal of biomolecular screening.

[3]  L. Gribaldo,et al.  Inhibition of CFU-E/BFU-E by 3'-azido-3'-deoxythymidine, chlorpropamide, and protoporphirin IX zinc (II): a comparison between direct exposure of progenitor cells and long-term exposure of bone marrow cultures. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  Hui Zhang,et al.  An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs , 2009, Artif. Intell. Medicine.

[5]  P. Cheverton,et al.  DX‐8951f: Summary of Phase I Clinical Trials , 2000, Annals of the New York Academy of Sciences.

[6]  Andrew G. Garrow,et al.  The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries. , 2012, Drug discovery today.

[7]  A. Friedenstein,et al.  THE DEVELOPMENT OF FIBROBLAST COLONIES IN MONOLAYER CULTURES OF GUINEA‐PIG BONE MARROW AND SPLEEN CELLS , 1970, Cell and tissue kinetics.

[8]  Wei Zhang,et al.  Pharmacophore, 3D‐QSAR, and Bayesian Model Analysis for Ligands Binding at the Benzodiazepine Site of GABAA Receptors: the Key Roles of Amino Group and Hydrophobic Sites , 2013, Chemical biology & drug design.

[9]  Angelo Vedani,et al.  In Silico Toxicology in Drug Discovery — Concepts Based on Three-dimensional Models , 2009, Alternatives to laboratory animals : ATLA.

[10]  J. Berger Statistical Decision Theory and Bayesian Analysis , 1988 .

[11]  J. P. Payne,et al.  The myelotoxicity of chloramphenicol: in vitro and in vivo studies: II: in vivo myelotoxicity in the B6C3F mouse , 1998, Human & experimental toxicology.

[12]  Sarah R. Langdon,et al.  Predicting cytotoxicity from heterogeneous data sources with Bayesian learning , 2010, J. Cheminformatics.

[13]  D. Parent-Massin,et al.  Myelotoxicity of trichothecenes and apoptosis: an in vitro study on human cord blood CD34+ hematopoietic progenitor. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.

[14]  Patrizia Crivori,et al.  Predicting Myelosuppression of Drugs from in Silico Models , 2011, J. Chem. Inf. Model..

[15]  J. Galsworthy A commentary , 1908 .

[16]  Huan-Zhang Xie,et al.  Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking. , 2012, Journal of molecular graphics & modelling.

[17]  Ka Fai Cedric Yiu,et al.  A new optimization algorithm for single hidden layer feedforward neural networks , 2013, Appl. Soft Comput..

[18]  Maurice Dickins,et al.  The importance of predictive ADME simulation. , 2002, Drug discovery today.

[19]  Chang-Ying Ma,et al.  In silico prediction of mitochondrial toxicity by using GA-CG-SVM approach. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[20]  G. C. Tiao,et al.  Bayesian inference in statistical analysis , 1973 .

[21]  N. Sanpera,et al.  Oestrogen-induced bone marrow aplasia in a dog with a Sertoli cell tumour. , 2002, The Journal of small animal practice.

[22]  D. Parent-Massin,et al.  In vitro toxicity of trichothecenes on human erythroblastic progenitors , 1997, Human & experimental toxicology.

[23]  Sean Ekins,et al.  A Predictive Ligand-Based Bayesian Model for Human Drug-Induced Liver Injury , 2010, Drug Metabolism and Disposition.

[24]  R. Parchment,et al.  Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning , 1993, Toxicologic pathology.

[25]  Irene Manou,et al.  Computational chemistry, systems biology and toxicology. Harnessing the chemistry of life: revolutionizing toxicology. A commentary , 2011, Journal of applied toxicology : JAT.

[26]  Dermot F McGinnity,et al.  Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics. , 2013, Molecular pharmaceutics.

[27]  Sean Ekins,et al.  Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. , 2010, Chemical research in toxicology.

[28]  Sandeep Modi Positioning ADMET in silico tools in drug discovery. , 2004, Drug discovery today.

[29]  J. Gisbert,et al.  Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review , 2008, The American Journal of Gastroenterology.

[30]  Hui Zhang,et al.  Rapid and accurate assessment of seizure liability of drugs by using an optimal support vector machine method. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[31]  R. Atsumi,et al.  A Predictive Model of Human Myelotoxicity Using Five Camptothecin Derivatives and the In vitro Colony-Forming Unit Granulocyte/Macrophage Assay , 2004, Clinical Cancer Research.

[32]  J. Stephenson,et al.  Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Naughton,et al.  Differential Effects of Drugs upon Hematopoiesis Can Be Assessed in Long-Term Bone Marrow Cultures Established on Nylon Screens , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[34]  D. Parent-Massin,et al.  Stem cells in myelotoxicity. , 2010, Toxicology.

[35]  A. Yan,et al.  In Silico Models to Discriminate Compounds Inducing and Noninducing Toxic Myopathy , 2012, Molecular informatics.

[36]  Sean Ekins,et al.  Progress in computational toxicology. , 2014, Journal of pharmacological and toxicological methods.

[37]  L. Gribaldo,et al.  In vitro myelotoxicity of environmental contaminants. , 1998, Environmental toxicology and pharmacology.